JGC
COGT icon

J. Goldman & Co’s Cogent Biosciences COGT Stock Holding History

J. Goldman & Co’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,600
Closed -$2.6M – 739
2026
Q1 		$2.6M Buy
+67,600
New +$2.5M 0.08% 278

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

J. Goldman & Co's COGT Position: Q2 2026 in Review

J. Goldman & Co reduced its Cogent Biosciences (COGT) stake by 18% in Q2 2026, selling an estimated $4.95M and leaving 637,994 shares worth $24.7M. The position accounts for 0.64% of the portfolio, ranked #30.

J. Goldman & Co first reported a position in COGT in Q4 2025 and has held it in 3 quarters since. The position peaked at $30M in Q1 2026. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • J. Goldman & Co held 637,994 shares of Cogent Biosciences worth $24.7M as of Q2 2026.
  • J. Goldman & Co sold 141,576 Cogent Biosciences shares in Q2 2026, an estimated $4.95M.
  • Cogent Biosciences made up 0.64% of J. Goldman & Co's portfolio in Q2 2026, its #30 holding.
  • J. Goldman & Co first reported a position in Cogent Biosciences in Q4 2025 and has held it in 3 quarters since.
  • J. Goldman & Co's Cogent Biosciences position peaked at $30M in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.